Why the study?
Does DWORF overexpression improve cardiac function and prevent pathological remodeling in a mouse model of dilated cardiomyopathy?
Does DWORF overexpression improve cardiac function and prevent pathological remodeling in a mouse model of dilated cardiomyopathy?
DWORF overexpression restores cardiac function and prevents pathological remodeling in a mouse model of dilated cardiomyopathy, establishing it as a potential therapeutic target for heart failure.
Supports DWORF as a target in murine cardiomyopathy models; leaves open translation to human heart failure.
Calcium (Ca²⁺) dysregulation is a hallmark of heart failure and is characterized by impaired Ca²⁺ sequestration into the sarcoplasmic reticulum (SR) by the SR-Ca²⁺-ATPase (SERCA). We recently discovered a micropeptide named DWORF (DWarf Open Reading Frame) that enhances SERCA activity by displacing phospholamban (PLN), a potent SERCA inhibitor. Here we show that DWORF has a higher apparent binding affinity for SERCA than PLN and that DWORF overexpression mitigates the contractile dysfunction associated with PLN overexpression, substantiating its role as a potent activator of SERCA. Additionally, using a well-characterized mouse model of dilated cardiomyopathy (DCM) due to genetic deletion of the muscle-specific LIM domain protein (MLP), we show that DWORF overexpression restores cardiac function and prevents the pathological remodeling and Ca²⁺ dysregulation classically exhibited by MLP knockout mice. Our results establish DWORF as a potent activator of SERCA within the heart and as an attractive candidate for a heart failure therapeutic.
No takes yet. Share an insight, caveat, or question.
Makarewich et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: